This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Dovitinib Lactate

Novartis AG

Drug Names(s): CHIR258, CHIR-258, TKI258, TKI-258

Description: TKI258 is an orally available multi-targeted tyrosine kinase inhibitor of angiogenic growth factors, inhibiting primarily fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) receptors, but also showing inhibition of platelet-derived growth factor (PDGF) receptor, FLT3, and KIT.

Dovitinib Lactate News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug